Key facts
- It has raised $2.0M; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include Plug and Play Tech Center, Innovate UK, Transpose Platform Management, Gaingels, Entrepreneurs First — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Axiom Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Axiom Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axiom Therapeutics
Developer of an advanced computational platform intended to treat undruggable diseases. The company offers a model that predicts covalent drug interactions with cancer-causing proteins, helping researchers in cancer treatment and accelerating research and treatment development.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 8
- Website
- axiom-therapeutics.com/
- Ownership
- Privately Held (backing)
Axiom Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axiom Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axiom Therapeutics in its N-PORT filings yet. We sweep new filings monthly.